Q32 Bio Inc. (0T6G)
LSE 
Summary
Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Q32 Bio (QTTB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Q32 Bio Inc. (0T6G) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Q32 Bio Inc. ever had a stock split?
Q32 Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jodie Pope Morrison CEO | LSE Exchange | 746964105 CUSIP |
| US Country | 22 Employees | - Last Dividend | 26 Mar 2024 Last Split | - IPO Date |
Overview
Q32 Bio Inc. is a pioneering force within the realm of clinical-stage biotechnology, specifically targeting the intricate realms of autoimmune and inflammatory diseases through the development of innovative biologic therapeutics. These therapeutics are expertly designed to modulate the essential regulators of two critical components of the human immune system: the innate and the adaptive systems. The objective behind their groundbreaking research and product development is to restore a harmonious balance within the body's immunity, aiming to offer relief and potential cures to individuals suffering from these debilitating conditions. Originally established under the name AdMIRx Inc., the enterprise underwent a strategic rebranding, adopting the name Q32 Bio Inc. in April 2020. This rebranding marked a new chapter in the company's journey since its inception in 2017. Operating from its headquarters in Waltham, Massachusetts, Q32 Bio is steadfast in its mission to advance the field of immunotherapy through its innovative approach to drug development.
Products and Services
- ADX-914 - A human anti-IL-7R antibody
ADX-914 stands at the forefront of Q32 Bio's ambitious pipeline, showcasing a novel approach to rebalancing the adaptive immune function. This therapeutic antibody specifically targets the IL-7 receptor, which plays a pivotal role in the pathogenesis of several autoimmune and inflammatory diseases. By modulating this receptor, ADX-914 aims to restore immune equilibrium, potentially offering a significant therapeutic benefit for patients afflicted by these conditions.
- ADX-097 - Targeted Therapeutic Modulation
As an integral component of Q32 Bio's innovative portfolio, ADX-097 embodies a cutting-edge approach to drug delivery and efficacy. Engineered to achieve optimal biodistribution to tissues and organs affected by autoimmune and inflammatory diseases, this product is designed to ensure durable pharmacokinetics and pharmacodynamics. The robust efficacy demonstrated by ADX-097 in preclinical models accentuates its potential to revolutionize the treatment landscape for patients battling these chronic conditions.
Contact Information
